BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
BUSINESS MODEL
BioInvent has three main areas for commercialization. The Company’s primary value drivers are clinical and preclinical development projects. BioInvent also has research and development collaborations based on the Company’s technology platform F.I.R.S.T™ and its antibody library n-CoDeR®.
BioInvent’s manufacturing facility provides capacity to produce antibodies for the Company’s preclinical studies and clinical trials, which is mandatory for a swift preclinical/ clinical development path. The manufacturing facility provides also the opportunity to manufacture and sell antibodies to external parties.
Learn more
Download our latest annual report to learn more about our strategy